No difference in degree of interstitial sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year

Journal of the American Society of Nephrology

Volumn 17, Issue 1, 2006, Pages 305-312

  Rowshani, Ajda T ^a,c   Scholten, Eduard M ^b   Bemelman, Frederike ^a   Eikmans, Michael ^b   Idu, Mirza ^a   Van Groningen, Marian C R ^b   Surachno, Janto S ^a   Mallat, Marko J K ^b   Paul, Leendert C ^b   De Fijter, Johan W ^b   Bajema, Ingeborg M ^b   Ten Berge, Ineke ^a   Florquin, Sandrine ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; DYE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SIRIUS RED; TSUKUBAENOLIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FIBROGENESIS; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY INTERSTITIUM; KIDNEY TRANSPLANTATION; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 33645451698     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005030249     Document Type: Article

References (41)

1. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333, 2003
2. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA: Molecular and structural consequences of early renal allograft injury. Kidney Int 61: 686-696, 2002
3. Colvin RB: Chronic allograft nephropathy. N Engl J Med 349: 2288-2290, 2003
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD: Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 78: 434-441, 2004
5. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD: Calcineurin inhibitor nephrotoxicity. Longitudinal assessment by protocol histology. Transplantation 78: 557-565, 2004
6. Sund S, Reisaeter AV, Fauchald P, Bentdal O, Hall KS, Hovig T: Living donor kidney transplants: A biopsy study 1 year after transplantation, compared with baseline changes and correlation to kidney function at 1 and 3 years. Nephrol Dial Transplant 14: 2445-2454, 1999
7. Nicholson ML, Bailey E, Williams S, Harris KP, Furness PN: Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation 68: 236-241, 1999
8. Nicholson ML, Bailey E, Williams S, Harris KP, Furness PN: Renal allograft survival can be predicted by histomorphometric assessment of extracellular matrix in 6-month protocol biopsies. Transplant Proc 30: 1305-1306, 1998
9. Nickerson P, Jeffery J, Gough J, McKenna R, Grimm P, Cheang M, Rush D: Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 9: 482-487, 1998
10. Seron D, Moreso F, Bover J, Condom E, Gil-Vernet S, Canas C, Fulladosa X, Torras J, Carrera M, Grinyo JM, Alsina J: Early protocol renal allograft biopsies and graft outcome. Kidney Int 51: 310-316, 1997
11. Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, Rush DN: Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 14: 1662-1668, 2003
12. Grimm PC, Nickerson P, Gough J, McKenna R, Jeffery J, Birk P, Rush DN: Quantitation of allograft fibrosis and chronic allograft nephropathy. Pediatr Transplant 3: 257-270, 1999
13. Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF: International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 44: 411-422, 1993
14. Isoniemi H, Taskinen E, Hayry P: Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 58: 1195-1198, 1994
15. Marcussen N, Olsen TS, Benediktsson H, Racusen L, Solez K: Reproducibility of the Banff classification of renal allograft pathology. Inter- and intraobserver variation. Transplantation 60: 1083-1089, 1995
16. Furness PN, Taub N: International variation in the interpretation of renal transplant biopsies: Report of the CERT-PAP Project. Kidney Int 60: 1998-2012, 2001
17. Moreso F, Seron D, Vitria J, Grinyo JM, Colome-Serra FM, Pares N, Serra J: Quantification of interstitial chronic renal damage by means of texture analysis. Kidney Int 46:1721-1727, 1994
18. Moreso F, Gratin C, Vitria J, Condom E, Poveda R, Cruzado JM, Grinyo JM, Alsina J, Seron D: Automatic evaluation of renal interstitial volume fraction. Transplant Proc 27: 2231-2232, 1995
19. Diaz Encarnacion MM, Griffin MD, Slezak JM, Bergstralh EJ, Stegall MD, Velosa JA, Grande JP: Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy. Am J Transplant 4: 248-256, 2004
20. Cosio FG, Pelletier RP, Sedmak DD, Falkenhain ME, Henry ML, Elkhammas EA, Davies EA, Bumgardner GL, Ferguson RM: Pathologic classification of chronic allograft nephropathy: Pathogenic and prognostic implications. Transplantation 67: 690-696, 1999
21. Davies DR, Bittmann I, Pardo J: Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation 69: SS11-SS13, 2000
22. Meyer MM, Munar M, Udeaja J, Bennett W: Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol 4: 1306-1315, 1993
23. Primmett DR, Levine M, Kovarik JM, Mueller EA, Keown PA: Cyclosporine monitoring in patients with renal transplants: Two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther Drug Monit 20: 276-283, 1998
24. Mahalati K, Belitsky P, West K, Kiberd B, Fraser A, Sketris I, Macdonald AS, McAlister V, Lawen J: Approaching the therapeutic window for cyclosporine in kidney transplantation: A prospective study. J Am Soc Nephrol 12: 828-833, 2001
25. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M7 Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RW, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JL, Talbot D, Pohanka E: Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64: 436-443, 1997
26. Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C III, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, van Veldhuisen P, Salm K, Tolzman D, Fitzsimmons WE: Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69: 834-841, 2000
27. Yang HC, Holman MJ, Langhoff E, Ulsh PJ, Dellock CA, Gupta M, Ahsan N: Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation-1-year follow-up of a prospective, randomized clinical trial. Transplant Proc 31: 1121-1124, 1999
28. Jurewicz WA: Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: An interim report. Transplant Proc 31: 64S-66S, 1999
29. Murphy GJ, Waller JR, Sandford RS, Furness PN, Nicholson ML: Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. Br J Surg 90: 680-686, 2003
30. Jurewicz WA: Tacrolimus versus cyclosporin immunosuppression: Long-term outcome in renal transplantation. Nephrol Dial Transplant 18[Suppl 1]: i7-i11, 2003
31. Waller JR, Murphy GJ, Metcalfe MS, Sandford RM, Pattenden CJ, Nicholson ML: Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy. Transplant Proc 34: 1587-1588, 2002
32. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR: Predicting glomerular filtration rate after kidney transplantation. Transplantation 59: 1683-1689, 1995
33. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999
34. Fernandez de Gatta MM, Garcia MJ, Lanao JM, Dominguez-Gil A: Bayesian forecasting in paediatric populations. Clin Pharmacokinet 31: 325-330, 1996
35. Dumont RJ, Ensom MH: Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet 38: 427-447, 2000
36. Gloor JM, Cohen AJ, Lager DJ, Grande JP, Fidler ME, Velosa JA, Larson TS, Schwab TR, Griffin MD, Prieto M, Nyberg SL, Sterioff S, Kremers WK, Stegall MD: Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 73: 1965-1968, 2002
37. Shishido S, Asanuma H, Nakai H, Mori Y, Satoh H, Kamimaki I, Hataya H, Ikeda M, Honda M, Hasegawa A: The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 14: 1046-1052, 2003
38. Rush DN, Henry SF, Jeffery JR, Schroeder TJ, Gough J: Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 57: 208-211, 1994
39. Rush DN, Jeffery JR, Gough J: Sequential protocol biopsies in renal transplant patients. Clinico-pathological correlations using the Banff schema. Transplantation 59: 511-514, 1995
40. Shishido S, Asanuma H, Nakai H, Mori Y, Satoh H, Kamimaki I, Hataya H, Ikeda M, Honda M, Hasegawa A: The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 14: 1046-1052, 2003
41. Rowshani AT, Florquin S, Bemelman F, Kummer JA, Hack CE, Ten Berge IJ: Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: A potential mechanism for stable renal function in patients with subclinical rejection. Kidney Int 66: 1417-1422, 2004